Noopept - Educational materials

Noopept is a novel cognitive enhancer that offers many health benefits demonstrated in numerous animal and human studies. It has the potential to protect brain cells from damage and degeneration. In particular, studies, discussed below, have shown that Noopept can inhibit oxidative damage and calcium overload, as well as suppress the mitochondrial apoptotic pathway. In addition, Noopept was found to reduce tau phosphorylation and restore altered PC12 neuronal cell morphology. These effects make Noopept a promising candidate for the treatment of neurodegenerative diseases such as Alzheimer's disease. In addition to its neuroprotective properties, Noopept has been shown to improve cognitive function and memory and stimulate the production of beta-amyloid antibodies, a protein associated with Alzheimer's disease. The research, discussed later, also suggested that Noopept may have anti-inflammatory effects, potentially useful in conditions such as stroke and chronic pain. Inflammation may play a role in this, so reducing inflammation may help improve symptoms and treatment outcomes. In addition to its potential for treating inflammation and pain, Noopept has shown potential for treating stroke. Studies have shown that Noopept can reduce brain damage and improve cognitive function in animals after stroke. This neuroprotective effect is believed to be due to the product's ability to inhibit oxidative stress and reduce inflammation in the brain. By protecting brain cells from damage and promoting regeneration after stroke, Noopept could be a valuable therapeutic preparation for stroke.

Unlike natural nootropics, Noopept can start working within minutes, and its effects can last for several hours. It is known to help with brain fog, memory and concentration.1 Noopept was first patented in Russia and later in the U.S. However, it is available as a supplement in the U.S. In animal studies, Noopept has been shown to increase the expression of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) in the hippocampal region, which may help brain cell growth and development. In addition, Noopept was found to have antioxidant properties, reducing oxidative stress and increasing antioxidant capacity. In human studies, it has been reported that Noopept may promote recovery from brain injury, but more research is needed to understand its potential mechanisms.

Interestingly, Noopept is up to 1,000 times more potent than Piracetam, the original racetam, and has 1.8 times fewer side effects associated with its use. It does not show up in blood samples when taken as a supplement. Instead, it raises the concentration of cycloproliglycine (CPG) in the brain. CPG is a dipeptide composed of proline and glycine that modulates acetylcholine transmission and AMPA receptor function.

Optimal modulation of dopamine and acetylcholine with Noopept

Noopept has also been studied for its potential role in balancing acetylcholine and dopamine levels in the brain. Acetylcholine is an important neurotransmitter involved in many functions, including memory, learning and muscle movement. Imbalances in acetylcholine levels have been linked to several conditions, including Alzheimer's disease and myasthenia gravis. Noopept has been shown to have protective effects against neurotoxicity and oxidative stress associated with imbalanced acetylcholine levels. Dopamine is another important neurotransmitter involved in mood, motivation and movement. Imbalances in dopamine levels have been linked to conditions such as depression, schizophrenia and Parkinson's disease. Noopept has been studied for its potential role in balancing dopamine levels in the brain, which could help improve symptoms. Overall, Noopept shows promise as a potential therapeutic agent for a variety of neurological conditions.

A study of Parkinson's disease presented evidence of Noopept's ability to modulate dopamine levels. Researchers have shown that intranasal administration of Forskolin and Noopept can effectively reverse Parkinson's symptoms. In rats, the study found significant improvements in motor symptoms, hind limb strength and prevention of dopamine neuron loss in affected rats. In addition, the treatment increased PKA activity and BDNF and NGF levels in the brain, while reducing α-synuclein aggregates in the cerebral cortex. This evidence suggests that Noopept in combination with Forskolin may offer a non-invasive, disease-modifying treatment for Parkinson's disease [1].

Why is an optimal balance of acetylcholine and dopamine important?

Imbalances in acetylcholine levels can have detrimental effects on human health. Low levels of acetylcholine (ACh) are associated with various conditions, such as Alzheimer's disease, Lambert-Eaton myasthenic syndrome and myasthenia gravis. These conditions can lead to a deficiency or reduced release of acetylcholine from nerve cells, or antibodies that interfere with acetylcholine receptors at the neuromuscular junction.

On the other hand, excessive acetylcholine can lead to a cholinergic crisis, affecting the nervous, respiratory, cardiovascular and digestive systems through excessive receptor stimulation. Stimulation of muscarinic receptors by excess Ach can cause salivation, frequent urination, diarrhea, gastrointestinal cramps, pain, vomiting and miosis. Stimulation of nicotinic receptors can cause muscle weakness, respiratory muscle weakness, tachycardia and hypertension. Stimulation of the central nervous system can cause seizures, coma, ataxia, slurred speech, agitation and restlessness. Therefore, maintaining a balance in acetylcholine levels is crucial to overall health and well-being [2].

As for optimal dopamine levels, it is an important neurotransmitter that plays a role in motivation, reward and motor control. When dopamine levels are low, it can lead to decreased motivation and excitement and is associated with conditions such as depression, schizophrenia and psychosis. Having too much dopamine or an imbalance in certain parts of the brain can increase competitiveness, aggression and poor impulse control. It can lead to ADHD, compulsive binge eating, addiction and gambling. Symptoms of dopamine imbalance can vary and can include muscle spasms, digestive problems, trouble sleeping, slow movements, fatigue, low libido and even hallucinations. Therefore, identifying the cause of dopamine imbalance and finding the right treatment is crucial to a person's health.

Scientific research on Noopept

Numerous animal and human studies have been conducted to investigate the potential health benefits of Noopept, making it a focus of neuroscience and pharmacology.

Potential role in stroke

Noopept, a neuroprotective and nootropic agent, has shown promise in treating mild cognitive impairment in post-stroke patients. A recent study involving 60 patients found that a daily dose of 20 mg of Noopept for two months significantly improved cognitive function [3]. In addition, Noopept reduces neurotoxicity caused by excess calcium, glutamate and free radicals. It has anti-inflammatory and anticoagulant properties, making it a good candidate for treating neurological conditions, including stroke [4].

In addition, in an animal model, Noopept (0.5 mg/kg) administered at different times after stroke caused 34.5% less brain damage than the control group, indicating its potential in treating stroke patients [5]. Also, another study of animals with frontal cortex thromboses found that GVS-111/Noopept (0.5 mg/kg/day, intravenously for ten days) improved cognitive function and reduced brain damage. The formulation showed memory-restoring and brain-protective properties, probably through increased neuronal plasticity, antioxidant activity and blocking voltage-gated ion channels [6]. In rats with chronic cerebral ischemia, Noopept (0.5 mg/kg) for seven days reduced neurological problems, increased survival, normalized behavior and prevented the accumulation of harmful byproducts [7]. In addition, one study showed that injections with Noopept reduced neurological deficits, restored behavior and provided antioxidant effects during chronic cerebral ischemia in rats. The peptide was effective during early and late ischemic preconditioning, with greater efficacy in the late phase [8].

Finally, in an in-vivo experiment, GVS-111/Noopept showed anticoagulant activity, exhibiting anticoagulant and fibrinolytic properties. Both intraperitoneal administration (1 mg/kg) and oral administration (10 mg/kg), administered daily for ten days, affected blood clotting, indicating the possibility of stroke management [9].

Possible anti-inflammatory effects

Medical studies have examined the anti-inflammatory effects of Noopept in rats and mice, comparing it with conventional analgesics. Noopept at doses of 1, 5 and 10 mg/kg effectively suppressed inflammation and reduced levels of the pro-inflammatory cytokines IL-6 and TNF-alpha [10]. In addition, one study showed that Noopept suppressed inflammation in a dose-dependent manner in rodents. The most significant effect observed in a model of chronic immune inflammation suggests that the anti-inflammatory activity may be due to antioxidant properties [11].

Noopept improves pain perception

For pain, Noopept showed protective effects against diabetes-related neurotoxicity and neuropathic pain by modulating TRPV1 activity. In rats, it reduced pain, blood glucose levels and apoptosis while increasing antioxidant levels. Noopept also decreased the expression of TRPV1, caspase-3 and -9, suggesting its potential in treating diabetes-induced neuropathic pain [12]. In another study, Noopept alleviated pain sensitivity in diabetic rats exposed to streptozotocin toxin. The study suggested that the neuroprotective and anti-inflammatory properties of Noopept may contribute to the analgesic effect [13].

Neuroprotective capabilities

Noopept is being studied in scientific research mainly for its neuroprotective properties. It shows neuroprotective and nootropic effects by exhibiting antioxidant activity, inhibiting lipid peroxidation and reducing free radicals. Studies have shown that it promotes memory by increasing BDNF levels and offers greater neuroprotection than Piracetam, making it a potential treatment for mental retardation and neurodegenerative disorders [14]. Also, in rats with bilateral frontal lobectomy, Noopept (0.5 mg/kg/day i.p. for nine days) improved active and passive avoidance performance and restored habituation, suggesting potential benefits in restoring memory and learning [15]. In addition, intraperitoneally or orally administered GVS-111/Noopept showed anti-amnestic effects in rats with frontal cortex damage and cerebral ischemia. It also improved passive avoidance reaction time, indicating potential for memory recall and learning [16].

In addition, Noopept increases NGF and BDNF expression in the hippocampus, promoting neuronal recovery and cognitive function. It has shown promising results in the prevention of Alzheimer's in patients with mild cognitive impairment [17]. In another study, Noopept (10 μM) protected PC12 cells, a model of Alzheimer's disease, from Aβ 25-35-induced toxicity. It improved cell viability, reduced levels of reactive oxygen species and calcium, and enhanced mitochondrial membrane potential, suggesting neuroprotective properties of Noopept in Alzheimer's treatment [18].

Moreover, in rats in a model resembling sporadic Alzheimer's disease, Noopept reduced metabolic changes, improved memory and affected multiple pathogenic pathways. It increased NGF and BDNF expression, stimulated antibody production, inhibited lipid peroxidation, activated antioxidant systems and reduced glutamate release [19]. Noopept also improved memory and immune response in mice with Alzheimer's-like symptoms, indicating its potential to reduce damaging proteins and protect brain cells, making it a possible treatment for cognitive problems caused by brain diseases [20]. Finally, in a cellular model of Alzheimer's, Noopept protected against the negative effects of Aβ25-35 on cell health, calcium balance, mitochondrial efficiency and nerve cell growth. It reduced oxidative damage, calcium excess and tau protein phosphorylation, suggesting potential efficacy for Alzheimer's treatment [21].

Immune support with Noopept

Noopept showed immunomodulatory properties in various research models. In a study on NMRI mice with olfactory bulbectomy, Noopept (0.01 mg/kg for 21 days) restored spatial memory in the Morris test and increased the level of antibodies against beta-amyloid [22]. Also, one study highlighted the immunostimulatory potential of Noopept. It enhanced immune responses, increased splenocyte proliferation and showed immunoprotective properties in animals with induced secondary immunodeficiency [23].

Memory support with Noopept

In an animal model of memory impairment, Noopept showed anti-amnesic activity. It reversed and improved spatial preference. The study showed that Noopept has potential as a treatment for memory impairment [24]. In rats with ischemic damage to the cerebral cortex and hereditary learning deficits, Noopept was found to improve memory retention and retrieval and normalize learning ability. The dipeptide improved all three stages of memory and had the most significant effect in animals with impaired memory function [25].

Potential of Noopept

Noopept's underestimated potential is related to its remarkable meteoadaptogenic properties. In a study involving healthy volunteers exposed to varying environmental conditions, Noopept demonstrated the ability to improve psychological and physical adaptability. It enhances mental performance in cold and hot climates and increases physical performance in hot conditions. These results highlight Noopept's unique ability to activate, support and restore mental and physical performance in rapidly changing environments [26].

The role of acetylcholine (Ach) in blood pressure regulation

ACh affects the regulation of blood pressure by ChAT+ T cells, inducing arterial vasodilation and promoting the migration of immune cells to sites of infection. Inhibition by PD-1 of ACh release by ChAT+ T cells can cause hypotension in some cases, as has been observed in animals and humans. It is noteworthy that T-cell activation is crucial for ACh release, and its inhibition by cyclosporin A can raise arterial pressure in transplant recipients [27].

Effects on the immune system, inflammation and other conditions

ACh plays a key role in various immune responses associated with multiple sclerosis, arthritis, diabetes, IBD and intestinal infections. In a mouse EAE assay, ACh expression in NK cells promotes migration to the CNS, reducing disease severity. In arthritis, ACh worsens the disease by promoting the migration of pro-inflammatory cells. However, β2AR activation can alleviate symptoms through α7nAChR signaling. In diabetes, ACh signaling through α7nAChR helps protect pancreatic β cells. ACh signaling reduces inflammation in IBD and intestinal infections and increases the expression of antimicrobial peptides. These findings highlight the diverse roles of ACh in immunity and potential therapeutic benefits in some diseases [27].

In addition, acetylcholine is a known neurotransmitter involved in the regulation of many biological processes. Alpha-7 nicotinic acetylcholine receptors (α7nAChRs) significantly affect immune cells. In an animal model, both non-neuronal and neuronal acetylcholine in the heart can attenuate inflammation and myocardial remodeling, providing important cardioprotection [28]. In addition, ACh regulates inflammation in central and peripheral systems. In patients with relapsing-remitting multiple sclerosis, lower serum ACh levels correlate with increased pro-inflammatory cytokines, suggesting impaired homeostasis of the cholinergic system in inflammation [29].

Who is noopept for?

Noopept will be a great remedy for people who have reduced levels of these two neurotransmitters:

• Dopamine
• Acetylcholine

People with low acetylcholine experience the following problems:

• Lack of appetite
• Slowed intestinal peristalsis
• Memory problems (forgetting words)
• Low pressure
• Increased inflammation
• Learning problems
• Dry mouth
• Dry eyes

People with low dopamine experience the following problems:

• Lack of motivation
• Lack of feeling any pleasure from something we previously enjoyed.
• Fatigue
• Low libido
• Sleep problems

Noopept can be used by people who want to increase efficiency during learning and the ability to concentrate. Here, however, you need to be careful, because a slight boost of acetylcholine can significantly increase our performance, but when we overdo it, side effects can occur. Noopept can increase appetite in sick people.

Noopept side effects

Side effects if they occur are most likely due to overstimulation of acetylcholine receptors. Too much acetylcholine can cause: heartburn, high blood pressure, sleep problems, tinnitus, inability to relax and anxiety. To avoid side effects, consider whether by chance our acetylcholine is already at high levels and we don't need noopept. The use of noopept should be started with minimal doses, e.g. 5mg, and gradually increased to 20mg per day. If there have already been side effects then most likely everything should return to normal after a few days of withdrawal. A substance that can help lower acetylcholine levels is scopolamine, available at the pharmacy. Taking noopept on a full stomach will result in a more mild and extended effect.

How to dose noopept?

Noopept dosage should start with 5mg to test individual tolerance. Then gradually you can increase to 20 mg per day. If there are no side effects then use daily for about 3 weeks, then it is worth taking a break for about a month. Doses can be broken up into several smaller doses throughout the day, this is because of the short half-life. Do not use in the evening due to the fact that noopept stimulates our nervous system to work, and in the evening we want to calm it down so we can recover with a deep sleep. Noopept has an uninteresting intense taste, to neutralize it we can add noopept to a piece of food.

Summary

Noopept has shown potential as a therapeutic agent in various neurological and immunological conditions, including stroke, Alzheimer's disease, multiple sclerosis and inflammation. This is due to its neuroprotective, immunostimulatory and anti-inflammatory properties. The diverse roles of acetylcholine (ACh) in the immune response underscore the importance of further research into Noopept's mechanisms of action and its potential clinical applications. Promising results have been obtained in animal and cellular studies, demonstrating Noopept's ability to enhance cognitive function, reduce neurotoxicity and improve neurological deficits. Its anti-inflammatory and anticoagulant properties also contribute to its potential in stroke treatment. Further research is needed to fully understand Noopept's interactions with the cholinergic system and may lead to novel therapeutic approaches in various diseases.

Disclaimer

This article was written for educational purposes and is intended to raise awareness of the substance being discussed. It is important to note that the substance discussed is a substance, not a specific product. The information contained in the text is based on available scientific research and is not intended to serve as medical advice or promote self-medication. The reader should consult any health and treatment decisions with a qualified health professional.

Sources

1. Dagda RK, Dagda RY, Vazquez-Mayorga E, Martinez B, Gallahue A. Intranasal Administration of Forskolin and Noopept Reverses Parkinsonian Pathology in PINK1 Knockout Rats. Int J Mol Sci. 2022 Dec 30;24(1):690. doi: 10.3390/ijms24010690. PMID: 36614135; PMCID: PMC9820624. https://pubmed.ncbi.nlm.nih.gov/36614135/
2. Adeyinka A, Kondamudi NP. Cholinergic Crisis. [Updated 2023 Feb 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482433/
3. Amelin AV, Iliukhina AIu, Shmonin AA. [Noopept in the treatment of mild cognitive impairment in patients with stroke]. Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(10 Pt 1):44-6. Russian. PMID: 22500312. https://pubmed.ncbi.nlm.nih.gov/22500312/
4. Ostrovskaia RU. Evoliutsiia problemy neĭroprotektsii [Evolution of the neuroprotection concept]. Eksp Klin Farmakol. 2003 Mar-Apr;66(2):32-7. Russian. PMID: 12962045. https://pubmed.ncbi.nlm.nih.gov/12962045/
5. Gavrilova SA, Us KS, Ostrovskaia RU, Koshelev VB. [Neuroprotective activity of the proline-containing dipeptide noopept on the model of brain ischemia induced by the middle cerebral artery occlusion]. Eksp Klin Farmakol. 2006 Jul-Aug;69(4):16-8. Russian. PMID: 16995431. https://pubmed.ncbi.nlm.nih.gov/16995431/
6. Ostrovskaya RU, Romanova GA, Barskov IV, Shanina EV, Gudasheva TA, Victorov IV, Voronina TA, Seredenin SB. Memory restoring and neuroprotective effects of the proline-containing dipeptide, GVS-111, in a photochemical stroke model. Behav Pharmacol. 1999 Sep;10(5):549-53. doi: 10.1097/00008877-199909000-00013. PMID: 10780261. https://pubmed.ncbi.nlm.nih.gov/10780261/
7. Zarubina IV, Shabanov PD. Noopept reduces the postischemic functional and metabolic disorders in the brain of rats with different sensitivity to hypoxia. Bull Exp Biol Med. 2009 Mar;147(3):339-44. doi: 10.1007/s10517-009-0504-4. PMID: 19529857. https://pubmed.ncbi.nlm.nih.gov/19529857/
8. Zarubina IV, Shabanov PD. Neuroprotective Effects of Peptides during Ischemic Preconditioning. Bull Exp Biol Med. 2016 Feb;160(4):448-51. doi: 10.1007/s10517-016-3193-9. epub 2016 Feb 23. PMID: 26902350. https://pubmed.ncbi.nlm.nih.gov/26902350/
9. Ostrovskaia RU, Liapina LA, Pastorova VE, Mirzoev TKh, Gudasheva TA, Seredenin SB, Ashmarin IP. Multicomponentĭ antitromboticheskiĭ éffekt neĭroprotektivnogo prolil-dipeptida GVS-111 i ego osnovnogo metabolita tsiklo-L-prolylglytsina [Multicomponent antithrombotic effect of the neuroprotective prolyl dipeptide GVS-111 and its major metabolite cyclo-L-prolylglycine]. Eksp Klin Farmakol. 2002 Mar-Apr;65(2):34-7. Russian. PMID: 12109290. https://pubmed.ncbi.nlm.nih.gov/12109290/
10. Alekseeva SV, Kovalenko LP, Tallerova AV, Gudasheva TA, Durnev AD. [An experimental study of the anti-inflammatory action of noopept and its effect on the level of cytokines]. Eksp Klin Farmakol. 2012;75(9):25-7. Russian. PMID: 23156084. https://pubmed.ncbi.nlm.nih.gov/23156084/
11. Kovalenko LP, Miramedova MG, Alekseeva SV, Gudasheva TA, Ostrovskaia RU, Seredenin SB. Protivovospalitel'nye svoĭstva noopepta (dipeptidnogo nootropa GVS-111) [Anti-inflammatory properties of noopept (dipeptide nootropic agent GVS-111)]. Eksp Klin Farmakol. 2002 Mar-Apr;65(2):53-5. Russian. PMID: 12109295. https://pubmed.ncbi.nlm.nih.gov/12109295/
12. Düzova H, Nazıroğlu M, Çiğ B, Gürbüz P, Akatlı AN. Noopept Attenuates Diabetes-Mediated Neuropathic Pain and Oxidative Hippocampal Neurotoxicity via Inhibition of TRPV1 Channel in Rats. Mol Neurobiol. 2021 Oct;58(10):5031-5051. doi: 10.1007/s12035-021-02478-8. epub 2021 Jul 9. PMID: 34241806. https://pubmed.ncbi.nlm.nih.gov/34241806/
13. Ostrovskaya RU, Ozerova IV, Gudascheva TA, Kapitsa IG, Ivanova EA, Voronina TA, Seredenin SB. Efficiency of noopept in streptozotocin-induced diabetes in rats. Bull Exp Biol Med. 2013 Jan;154(3):334-8. doi: 10.1007/s10517-013-1944-4. PMID: 23484194. https://pubmed.ncbi.nlm.nih.gov/23484194/
14. Pelsman A, Hoyo-Vadillo C, Gudasheva TA, Seredenin SB, Ostrovskaya RU, Busciglio J. GVS-111 prevents oxidative damage and apoptosis in normal and Down's syndrome human cortical neurons. Int J Dev Neurosci. 2003 May;21(3):117-24. doi: 10.1016/s0736-5748(03)00031-5. PMID: 12711349. https://pubmed.ncbi.nlm.nih.gov/12711349/
15. Ostrovskaya RU, Romanova GA, Trofimov SS, Gudasheva TA, Voronina TA, Halikas JA, Seredenin SB. The novel substituted acylproline-containing dipeptide, GVS-111, promotes the restoration of learning and memory impaired by bilateral frontal lobectomy in rats. Behav Pharmacol. 1997 Jun;8(2-3):261-8. PMID: 9833021. https://pubmed.ncbi.nlm.nih.gov/9833021/
16. Romanova GA, Mirzoev TK, Barskov IV, Victorov IV, Gudasheva TA, Ostrovskaya RU. Antiamnesic effect of acyl-prolyl-containing dipeptide (GVS-111) in compression-induced damage to frontal cortex. Bull Exp Biol Med. 2000 Sep;130(9):846-8. PMID: 11177261. https://pubmed.ncbi.nlm.nih.gov/11177261/
17. Ostrovskaya RU, Gudasheva TA, Zaplina AP, Vahitova JV, Salimgareeva MH, Jamidanov RS, Seredenin SB. Noopept stimulates the expression of NGF and BDNF in rat hippocampus. Bull Exp Biol Med. 2008 Sep;146(3):334-7. doi: 10.1007/s10517-008-0297-x. PMID: 19240853. https://pubmed.ncbi.nlm.nih.gov/19240853/
18. Ostrovskaya RU, Vakhitova YV, Kuzmina USh, Salimgareeva MKh, Zainullina LF, Gudasheva TA, Vakhitov VA, Seredenin SB. Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation. J Biomed Sci. 2014 Aug 6;21(1):74. doi: 10.1186/s12929-014-0074-2. PMID: 25096780; PMCID: PMC4422191. https://pubmed.ncbi.nlm.nih.gov/25096780/
19. Ostrovskaia RU, Tsaplina AP, Vakhitova IuV, Salimgareeva MKh, Iamidanov RS. [Effect of the novel nootropic and neuroprotective dipeptide noopept on the streptozotocin-induced model of sporadic Alzheimer disease in rats]. Eksp Klin Farmakol. 2010 Jan;73(1):2-6. Russian. PMID: 20184279. https://pubmed.ncbi.nlm.nih.gov/20184279/
20. Ostrovskaya RU, Gruden MA, Bobkova NA, Sewell RD, Gudasheva TA, Samokhin AN, Seredinin SB, Noppe W, Sherstnev VV, Morozova-Roche LA. The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model. J Psychopharmacol. 2007 Aug;21(6):611-9. doi: 10.1177/0269881106071335. Epub 2006 Nov 8. PMID: 17092975. https://pubmed.ncbi.nlm.nih.gov/17092975/
21. Ostrovskaya, R.U., Vakhitova, Y.V., Kuzmina, U.S. et al. Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation. J Biomed Sci 21, 74 (2014). https://doi.org/10.1186/s12929-014-0074-2 https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-014-0074-2
22. Bobkova NV, Gruden' MA, Samokhin AN, Medvinskaia NI, Morozova-Roch L, Uudasheva TA, Ostrovskaia RU, Seredinin SB. [Noopept improves the spatial memory and stimulates prefibrillar beta-amyloid(25-35) antibody production in mice]. Eksp Klin Farmakol. 2005 Sep-Oct;68(5):11-5. Russian. PMID: 16277202. https://pubmed.ncbi.nlm.nih.gov/16277202/
23. Kovalenko LP, Shipaeva EV, Alekseeva SV, Pronin AV, Durnev AD, Gudasheva TA, Ostrovskaya RU, Seredenin SB. Immunopharmacological properties of noopept. Bull Exp Biol Med. 2007 Jul;144(1):49-52. English, Russian. doi: 10.1007/s10517-007-0251-3. PMID: 18256750. https://pubmed.ncbi.nlm.nih.gov/18256750/
24. Radionova KS, Belnik AP, Ostrovskaya RU. Original nootropic drug noopept prevents memory deficit in rats with muscarinic and nicotinic receptor blockade. Bull Exp Biol Med. 2008 Jul;146(1):59-62. doi: 10.1007/s10517-008-0209-0. PMID: 19145351. https://pubmed.ncbi.nlm.nih.gov/19145351/
25. Romanova GA, Shakova FM, Gudasheva TA, Ostrovskaya RU. Impairment of learning and memory after photothrombosis of the prefrontal cortex in rat brain: effects of Noopept. Bull Exp Biol Med. 2002 Dec;134(6):528-30. doi: 10.1023/a:1022940507519. PMID: 12660828. https://pubmed.ncbi.nlm.nih.gov/12660828/
26. Shabanov PD, Ganapol'skiĭ VP, Aleksandrov PV. [Meteoadaptogenic properties of peptide drugs in healthy volunteers]. Eksp Klin Farmakol. 2007 Nov-Dec;70(6):41-7. Russian. PMID: 18318195. https://pubmed.ncbi.nlm.nih.gov/18318195/
27. Cox, M. A., Bassi, C., Saunders, M. E., Nechanitzky, R., Morgado-Palacin, I., Zheng, C., & Mak, T. W. (2020). Beyond neurotransmission: acetylcholine in immunity and inflammation. Journal of internal medicine, 287(2), 120-133. https://onlinelibrary.wiley.com/doi/full/10.1111/joim.13006
28. Lu, J., & Wu, W. (2021). Cholinergic modulation of the immune system-A novel therapeutic target for myocardial inflammation. International Immunopharmacology, 93, 107391. https://www.sciencedirect.com/science/article/pii/S1567576921000278
29. Di Bari M, Reale M, Di Nicola M, Orlando V, Galizia S, Porfilio I, Costantini E, D'Angelo C, Ruggieri S, Biagioni S, Gasperini C, Tata AM. Dysregulated Homeostasis of Acetylcholine Levels in Immune Cells of RR-Multiple Sclerosis Patients. Int J Mol Sci. 2016 Nov 30;17(12):2009. doi: 10.3390/ijms17122009. PMID: 27916909; PMCID: PMC5187809. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187809/